Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma

Journal of Proteome Research

Volumn 13, Issue 11, 2014, Pages 4581-4593

  Johnson, Hannah ^a,c   White, Forest M ^a,b  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

glioblastoma multiforme; iTRAQ; mass spectrometry; signal transduction; signaling; tyrosine phosphorylation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; FOCAL ADHESION KINASE; INTEGRIN; NESTIN; PHOSPHOPROTEIN ASSOCIATED WITH GLYCOSPHINGOLIPID MICRODOMAINS 1; PHOSPHOTYROSINE; PROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; SHPS1 PROTEIN; TALIN; TENSIN 2; UNCLASSIFIED DRUG; VIMENTIN; NITROGEN;

ADULT; AGED; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; FEMALE; FREEZING; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; ISOELECTRIC FOCUSING; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; GENE EXPRESSION REGULATION; GENETICS; HISTOLOGY; LABORATORY DIAGNOSIS; PATHOPHYSIOLOGY; PHOSPHORYLATION; PHYSIOLOGY; PROCEDURES; PROTEOMICS;

FREEZING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; IMMUNOBLOTTING; MASS SPECTROMETRY; NITROGEN; PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SPECIMEN HANDLING; TISSUE EMBEDDING;

EID: 84908880180     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr500418w     Document Type: Article

References (37)

1. Stupp, R. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma N. Engl. J. Med. 2005, 352 (10) 987-96
2. Stupp, R. Effects of radiotherapy with concomitant and adjuvant Temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol. 2009, 10 (5) 459-66
3. Furnari, F. B. Malignant astrocytic glioma: genetics, biology, and paths to treatment Genes Dev. 2007, 21 (21) 2683-710
4. Network, T. C. G. A. R. Comprehensive genomic characterization defines human glioblastoma genes and core pathways Nature 2008, 455 (7216) 1061-1068
5. Guha, A. Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop Int. J. Cancer 1995, 60 (2) 168-73
6. Verhaak, R. G. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 Cancer Cell 2010, 17 (1) 98-110
7. Huang, P. H. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (31) 12867-12872
8. Brennan, C. Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations PLoS One 2009, 4 (11) e7752
9. Phillips, H. S. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis Cancer Cell 2006, 9 (3) 157-73
10. Holdhoff, M. Use of personalized molecular biomarkers in the clinical care of adults with glioblastomas J. Neurooncol. 2012, 110 (2) 279-85
11. Huang, P. H. Uncovering therapeutic targets for glioblastoma: a systems biology approach Cell Cycle 2007, 6 (22) 2750-4
12. Gopal, Y. N. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells Cancer Res. 2010, 70 (21) 8736-47
13. Gujral, T. S. Profiling phospho-signaling networks in breast cancer using reverse-phase protein arrays Oncogene 2013, 32 (29) 3470-6
14. Drake, J. M. Oncogene-specific activation of tyrosine kinase networks during prostate cancer progression Proc. Natl. Acad. Sci. U. S. A. 2012, 109 (5) 1643-8
15. Rikova, K. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer Cell 2007, 131 (6) 1190-203
16. Johnson, H. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts Mol. Cell. Proteomics 2012, 11 (12) 1724-40
17. Camphausen, K. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions Proc. Natl. Acad. Sci. U. S. A 2005, 102 (23) 8287-92
18. Steu, S. A procedure for tissue freezing and processing applicable to both intra-operative frozen section diagnosis and tissue banking in surgical pathology Virchows Arch. 2008, 452 (3) 305-12
19. Loken, S. D.; Demetrick, D. J. A novel method for freezing and storing research tissue bank specimens Hum. Pathol. 2005, 36 (9) 977-80
20. Chaurand, P. Monitoring mouse prostate development by profiling and imaging mass spectrometry Mol. Cell. Proteomics 2008, 7 (2) 411-23
21. Zhang, Y. Time-resolved Mass Spectrometry of Tyrosine Phosphorylation Sites in the Epidermal Growth Factor Receptor Signaling Network Reveals Dynamic Modules Mol. Cell. Proteomics 2005, 4 (9) 1240-1250
22. Curran, T. G. Computer aided manual validation of mass spectrometry-based proteomic data Methods 2013, 61 (3) 219-26
23. Jones, P. PRIDE: a public repository of protein and peptide identifications for the proteomics community Nucleic acids res. 2006, 34, D659-63
24. Gerlinger, M. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing N. Engl. J. Med. 2012, 366 (10) 883-92
25. Sottoriva, A. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics Proc. Natl. Acad. Sci. U. S. A 2013, 110 (10) 4009-14
26. Mitra, S. K.; Schlaepfer, D. D. Integrin-regulated FAK-Src signaling in normal and cancer cells Curr. Opin. Cell Biol. 2006, 18 (5) 516-523
27. Bertotti, A. Beta4 integrin activates a Shp2-Src signaling pathway that sustains HGF-induced anchorage-independent growth J. Cell Biol. 2006, 175 (6) 993-1003
28. Dutta, U.; Shaw, L. M. A key tyrosine (Y1494) in the beta4 integrin regulates multiple signaling pathways important for tumor development and progression Cancer Res. 2008, 68 (21) 8779-87
29. Huang, Y. Z. Erbin suppresses the MAP kinase pathway J. Biol. Chem. 2003, 278 (2) 1108-14
30. Cheung, A. K. Cysteine-rich intestinal protein 2 (CRIP2) acts as a repressor of NF-kappaB-mediated proangiogenic cytokine transcription to suppress tumorigenesis and angiogenesis Proc. Natl. Acad. Sci. U. S. A 2011, 108 (20) 8390-5
31. Hui, A. B. Detection of recurrent chromosomal gains and losses in primary nasopharyngeal carcinoma by comparative genomic hybridisation Int. J. Cancer 1999, 82 (4) 498-503
32. Sutton, P. Lyn, a Src family kinase, regulates activation of epidermal growth factor receptors in lung adenocarcinoma cells Mol. Cancer 2013, 12, 76
33. Rubbi, L. Global Phosphoproteomics Reveals Crosstalk Between Bcr-Abl and Negative Feedback Mechanisms Controlling Src Signaling Sci. Signaling 2011, 4 (166) ra18
34. Takada, T. Roles of the complex formation of SHPS-1 with SHP-2 in insulin-stimulated mitogen-activated protein kinase activation J. Biol. Chem. 1998, 273 (15) 9234-42
35. Cheung, H. C. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines Brain 2009, 132 (Pt 8) 2277-88
36. Wu, D. An alternative splicing isoform of eukaryotic initiation factor 4H promotes tumorigenesis in vivo and is a potential therapeutic target for human cancer Int. J. Cancer 2011, 128 (5) 1018-30
37. Lefave, C. V. Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas EMBO J. 2011, 30 (19) 4084-97